ClinConnect ClinConnect Logo
Search / Trial NCT06058585

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Launched by THE GEORGE INSTITUTE · Sep 21, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Chronic Kidney Disease Mineralocorticoid Receptor Antagonist Finerenone

ClinConnect Summary

The CAPTIVATE trial is a large international study looking at different treatments for people with chronic kidney disease (CKD). The main goal of this trial is to find the best way to slow down the progression of CKD, which helps prevent more serious conditions like kidney failure. If you're an adult aged 18 or older with a known case of CKD and are currently receiving standard treatment, you might be eligible to participate in this trial.

Participants in the CAPTIVATE trial will be randomly assigned to receive different treatments or combinations of treatments. This means you may receive a treatment that is part of the study, which could help researchers learn more about what works best. It’s important to note that if you are planning to start kidney replacement therapy or have a life expectancy of less than six months, you won’t be able to join this study. Overall, this trial aims to improve treatment options for CKD and ultimately enhance the quality of life for those affected by this condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years
  • 2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
  • 3. Currently receiving standard of care treatment according to treating physician
  • 4. Eligible for randomisation in at least one recruiting domain-specific appendix
  • 5. Participant and treating physician are willing and able to perform trial procedures
  • Exclusion Criteria:
  • 1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  • 2. Life expectancy less than 6 months

About The George Institute

The George Institute for Global Health is a leading research organization dedicated to improving health outcomes through innovative clinical trials and groundbreaking research. Based in Australia, the institute focuses on addressing major health challenges, particularly in the areas of chronic diseases, cardiovascular health, and health equity. With a commitment to translating scientific discoveries into real-world applications, The George Institute collaborates with global partners to advance knowledge and implement effective health interventions. Its multidisciplinary team of researchers employs rigorous methodologies to ensure high-quality evidence that informs policy and practice, ultimately striving to enhance public health on a global scale.

Locations

Westmead, New South Wales, Australia

Garran, Australian Capital Territory, Australia

Heidelberg, Victoria, Australia

New Lambton Heights, New South Wales, Australia

Kogarah, New South Wales, Australia

Elizabeth Vale, South Australia, Australia

Douglas, Queensland, Australia

Chennai, Tamil Nadu, India

Southport, Queensland, Australia

Birtinya, Queensland, Australia

Kolkata, West Bengal, India

Ipswich, Queensland, Australia

Visakhapatnam, Andra Pradesh, India

Wayanad, Kerala, India

Siliguri, West Bengal, India

Kingswood, New South Wales, Australia

Murdoch, Western Australia, Australia

Patna, Bihar, India

Mangaluru, Karnataka, India

Hyderabad, Kothaguda, Telangana, India

Lucknow, Uttar Pradesh, India

Dehradun, Uttarakhand, India

Anandapur, East Kolkata Township, West Bengal, India

Hastings, Hawkes Bay, New Zealand

Auckland, , New Zealand

Auckland, , New Zealand

Meppadi, Kerala, India

Indore, Madhya Pradesh, India

Hyderabad, Telangana, India

Hyderabad, Telangana, India

Patients applied

0 patients applied

Trial Officials

Sradha Kotwal

Study Chair

The George Institute

Hiddo Lambers Heerspink

Study Chair

The George Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported